FDA 483 - Aspen SA Sterile Operations (Pty) Ltd. - September 17, 2024

During an inspection from September 9-17, 2024, the FDA issued a Form 483 to Aspen SA Sterile Operations (Pty) Ltd., a sterile over-the-counter drug manufacturer in South Africa. The inspection revealed twelve significant observations concerning violations of Current Good Manufacturing Practices (CGMP).

Key issues included a systemic failure to prevent microbiological contamination during aseptic filling operations, with operators frequently reaching over open sterile products and inadequate adherence to aseptic procedures. The firm also lacked robust validation of its aseptic processes, evidenced by deficient air profile studies and media fills that did not accurately simulate routine production challenges.

Major concerns involved the consistent failure to thoroughly investigate quality discrepancies. This included numerous unaddressed stability failures for US market products, container closure integrity issues, repeated microbial contamination deviations (including Burkholderia cepacia group), and various packaging defects leading to customer complaints, all without comprehensive root cause analysis or effective corrective actions. Furthermore, the company demonstrated inadequate laboratory controls with missing or unjustified impurity specifications and poor data integrity practices for computerized systems, including unreported failing test results and shared passwords. Deficiencies extended to inadequate cleaning procedures, environmental monitoring, inappropriate personnel clothing, and issues with equipment design and bulk hold time studies.

These observations collectively indicate a serious breakdown in quality systems, raising concerns about the sterility, identity, strength, quality, and purity of drug products manufactured for the US market. Aspen SA Sterile Operations is required to promptly address these findings with comprehensive corrective and preventive actions to ensure compliance with FDA regulations.